What is the efficacy of cilostazol for the prevention of secondary stroke in patients with ischemic stroke related to small vessel disease?
Cilostazol has been studied as an alternative to aspirin therapy for ischemic stroke related to small vessel disease. In the CSPS trial (Cilostazol for Prevention of Secondary Stroke), cilostazol was compared with placebo in 1095 Japanese patients with noncardioembolic ischemic stroke. There was a significant reduction in the risk of recurrent stroke in the cilostazol treatment group and in participants with lacunar stroke in the subgroup analysis.